With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca‘s total revenues) rose 18% in the second quarter of 2025, generating $6.3 ...

Britain’s cash-strapped Labour government cannot fold to every corporate lobbying campaign. But it ought to heed Soriot and ...

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

AstraZeneca and Daiichi Sankyo on Friday secured U.S. approval that broadens the use of their therapy Enhertu, for patients with breast cancer, and paves the way for billions in sales.

AstraZeneca said on Monday a mid-stage trial of its cancer drug Enhertu, co-developed with Daiichi Sankyo, showed positive results across multiple HER2-expressing advanced solid tumours in heavily ...

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said, "DESTINY-Breast06 shows that Enhertu could become a new standard of care for patients with HER2-low and HER2-ultralow ...

(Reuters) -AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another ...

AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor- positive, HER2-low or HER2-ultralow ...

Pharma ASCO: AstraZeneca, Daiichi’s Enhertu could transform breast cancer treatment with landmark HER2-low show By Angus Liu Jun 5, 2022 8:00am ASCO 2022 Enhertu breast cancer HER2 ...

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Commission has granted conditional approval to their cancer drug, Enhertu (trastuzumab deruxtecan) for third ...

AstraZeneca's cancer medicine Enhertu, a drug developed jointly with Japan's Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022.